Difference between revisions of "Paroxetine-mirtazapine"

From Psychiatrienet
Jump to: navigation, search
 
(3 intermediate revisions by 2 users not shown)
Line 5: Line 5:
 
{{downparox}}
 
{{downparox}}
 
| start =  
 
| start =  
* '''Day 1:''' simultaneously start administration of mirtazapine is a low dosage of 15 mg/day.  
+
* '''Day 8:''' start mirtazapine in a low dosage of 15 mg/day.  
* '''Day 8:''' continue administration of mirtazapine in a dosage of 15-30 mg/day.
+
* '''Day 15:''' if necessary gradually increase dosage of mirtazapine to target dose.
* '''Day 22:''' if necessary increase administration of mirtazapine.}}
+
|info=
 +
{{SSRI14d}}
 +
}}

Latest revision as of 16:55, 24 February 2023

paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine
Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine

Switch medication from paroxetine to mirtazapine.[1] [2]

Nietinrijdenbord.png Stop paroxetine
  • Day -7: reduce dosage of paroxetine to 20 mg/day, if this dosage is > 20 mg/day.
  • Day 0: dosage of paroxetine is 20 mg/day.
  • Day 1: reduce dosage of paroxetine to 10 mg/day.
  • Day 8: reduce dosage of paroxetine to 5 mg/day.
  • Day 15: stop administration of paroxetine.
Eenrichtingbord.png Start mirtazapine
  • Day 8: start mirtazapine in a low dosage of 15 mg/day.
  • Day 15: if necessary gradually increase dosage of mirtazapine to target dose.
Infobord.png More information
  • The reduction of the SSRI doses in 7-14 days could cause emotional instability, headache and flu-like symptoms. One could extend this period.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.